Kantarjian, H M <br/><br/>
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 1992 
 - 398-405 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1992.10.3.398  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Blast Crisis--drug therapy<br/>Bone Marrow Diseases--chemically induced<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Granulocyte-Macrophage Colony-Stimulating Factor--therapeutic use<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Leukemia, Myeloid, Accelerated Phase--drug therapy<br/>Middle Aged<br/>Prognosis<br/>Remission Induction<br/>Survival Analysis